China's medical products administrator approved Shanghai Haixin Group (SHA:600851) subsidiary Jiangxi Gannan Haixin Pharmaceutical's drug registration and active pharmaceutical ingredient application for its dexmedetomidine hydrochloride injection.
Dexmedetomidine hydrochloride is indicated for sedation during endotracheal intubation and mechanical ventilation for patients undergoing surgery, according to a Tuesday filing with the Shanghai Stock Exchange.
The drug is also used to sedate patients who have been intubated and inserted with a ventilator during intensive care treatment, the filing said.
Shares in the drug company closed 3% lower during Tuesday's afternoon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.